PharmaShots | Incisive News in 3 Shots

Subscribe Now

Nykode Therapeutics

Nykode Therapeutics Receives US FDA’s IND Approval for P-II Trial (VB-C-04) to Evaluate VB10.16 in HPV16-Positive Cervical Cancer

Nykode Therapeutics Receives US FDA’s IND Approval for P-II Trial (VB-C-04) to Evaluate VB10.16 in HPV16-Positive Cervical Cancer

September 5, 2023

Nykode Therapeutics Expands its Clinical Collaboration and Supply Agreement with Roche to Evaluate VB10.16 for Advanced Cervical Cancer

Nykode Therapeutics Expands its Clinical Collaboration and Supply Agreement with Roche to Evaluate VB10.16 for Advanced Cervical C...

June 1, 2023

Nykode Therapeutics Reports Final P-II Trial (VB-C-02) Results of VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer

Nykode Therapeutics Reports Final P-II Trial (VB-C-02) Results of VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer

April 19, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us